Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899215 | 0.87 | PTGES (0.49) | PTGESTRPV1 | |
| SCHEMBL23512223 | 0.87 | PTGES (0.49) | PTGESTRPV1 | |
| SCHEMBL30899213 | 0.82 | NPC1 (0.54) | PTGESTRPV1 | |
| SCHEMBL21645632 | 0.82 | NPC1 (0.54) | PTGESTRPV1 | |
| SCHEMBL21645366 | 0.82 | PTGES (0.52) | PTGES | |
| SCHEMBL30899214 | 0.82 | PTGES (0.52) | PTGES | |
| SCHEMBL19064507 | 0.81 | P2RX1 (0.55) | PTGES | |
| SCHEMBL29577337 | 0.81 | P2RX1 (0.55) | PTGES | |
| SCHEMBL21645628 | 0.78 | PTGES (0.54) | PTGES | |
| SCHEMBL30899219 | 0.78 | PTGES (0.54) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DUKE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| WO-2020028392-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DNER, SFRP1, WNT1 | PTGES 1773/4885TRPV1 1540/4885 |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DNER, SFRP1, WNT1 | PTGES 1773/4885TRPV1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.